Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Germline RUNX1 Deficiency
NCT06090669Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imatinib in Familial platelet disorder with associated myeloid malignancy (FPDMM) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Safety of imatinib at 3 months and Dose of imatinib for dose expansion at 3 months. Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
Familial platelet disorder with associated myeloid malignancy (FPDMM)
Beyond the preview
Go deeper on NCT06090669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090669.